Yeargin J, Cheng J, Haas M
Dept. Biology/Cancer Center, UCSD, La Jolla 92093-0063.
Leukemia. 1992;6 Suppl 3:85S-91S.
The tumor suppressor gene p53 has been shown to be mutated in 50% of acute lymphoblastic T-cell-leukemia (T-ALL) cell lines, all of which were established from T-ALL cases in relapse. In these lines both alleles of the p53 gene were independently affected by point mutation. In contrast, in human solid tumors possessing a mutated p53 allele, the second wild-type p53 suppressor allele is often lost by deletion rather than altered by mutation. This suggests that in T-ALL cell lines, the product encoded by the second mutated allele provides the cells with an additional oncogenic stimulus, beyond the loss of suppressive activity. While different p53 mutations have been shown to possess differential oncogenic potential in the p53 plus ras cotransformation assay, in T-ALL cells different mutations may in addition possess distinct functions, further contributing to the tumorigenic phenotype.
肿瘤抑制基因p53已被证明在50%的急性淋巴细胞性T细胞白血病(T-ALL)细胞系中发生突变,所有这些细胞系均建立于复发的T-ALL病例。在这些细胞系中,p53基因的两个等位基因均独立受到点突变的影响。相比之下,在具有突变p53等位基因的人类实体瘤中,第二个野生型p53抑制等位基因常常通过缺失而丢失,而非通过突变改变。这表明在T-ALL细胞系中,由第二个突变等位基因编码的产物为细胞提供了额外的致癌刺激,超出了抑制活性丧失的影响。虽然不同的p53突变在p53与ras共转化试验中已显示出不同的致癌潜力,但在T-ALL细胞中,不同的突变可能还具有独特的功能,进一步促成致瘤表型。